N-cadherin antagonists as oncology therapeutics

Orest W. Blaschuk

Division of Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada H3A 1A1

The cell adhesion molecule (CAM), N-cadherin, has emerged as an important oncology therapeutic target. N-cadherin is a transmembrane glycoprotein mediating the formation and structural integrity of blood vessels. Its expression has also been documented in numerous types of poorly differentiated tumours. This CAM is involved in regulating the proliferation, survival, invasiveness and metastasis of cancer cells. Disruption of N-cadherin homophilic intercellular interactions using peptide or small molecule antagonists is a promising novel strategy for anti-cancer therapies. This review discusses: the discovery of N-cadherin, the mechanism by which N-cadherin promotes cell adhesion, the role of N-cadherin in blood vessel formation and maintenance, participation of N-cadherin in cancer progression, the different types of N-cadherin antagonists and the use of N-cadherin antagonists as anti-cancer drugs.

1. Introductory comments concerning N-cadherin and calcium-dependent cell adhesion

Neural (N)-cadherin is an integral membrane, calcium-binding glycoprotein that mediates the intercellular adhesion of neuronal cells and many other types of non-neuronal cells [1–3]. The extracellular domain of N-cadherin is composed of five subdomains (EC1–EC5; figure 1) [1,2]. Three calcium ions bind between each successive duo of subdomains (i.e. EC1-EC2, EC2-EC3, EC3-EC4 and EC4-EC5). The binding of calcium ions stabilizes the elongated, curved structure of N-cadherin thus enabling the proper function of this cell adhesion molecule (CAM) [2].

Cells comprising vertebrate tissues have been shown to possess calcium-dependent and calcium-independent adhesion mechanisms [4,5]. The calcium-dependent adhesion mechanism is resistant to proteolysis in the presence of calcium, whereas the calcium-independent adhesion mechanism is not. Treatment of cells with proteases (e.g. trypsin) in the presence of ethylene glycol tetraacetic acid (EGTA, which results in the removal of calcium from the medium) abolishes calcium-dependent adhesion.

N-cadherin was identified in the 1980s by two groups: Volk & Geiger [6–8] and Hatta & Takeichi [9]. Volk and Geiger were seeking to elucidate the CAMs present in a particular intercellular junction, known as the adherens junction. They prepared an intercalated disc-enriched membrane fraction containing adherens junctions from chicken cardiac muscle and then extracted it with detergent [6]. This detergent extract was used to immunize mice and generate hybridomas. One of the hybridomas was found to secrete a monoclonal antibody (designated ID-7.2.3) that recognized a membrane glycoprotein component of adherens junctions present in intercalated discs, as judged by immunoelectron microscopy [6,7]. Volk and Geiger named this glycoprotein adherens junction-specific CAM (A-CAM) [7]. They proceeded to demonstrate that A-CAM was degraded by trypsin in the presence of EGTA. It is noteworthy that the formation of adherens junctions does not occur in the absence of calcium. Finally, monovalent Fab fragments of ID-7.2.3 were shown to be capable of blocking the formation of adherens junctions by cultured cells [8]. Collectively, these observations provided strong evidence that A-CAM was directly involved in mediating the calcium-dependent formation of adherens junctions. It was later shown that A-CAM was identical to N-cadherin [10].
monomer inserts into an apposed hydrophobic pocket containing an Ala residue.

2. Mechanism by which N-cadherin promotes cell adhesion

N-cadherin monomers exist in many different states within the plane of the cell’s plasma membrane and at intercellular adhesive contacts, where they function as homophilic CAMs [2,12,13]. In order to form stable intercellular adhesive junctions, the monomers apparently must interact within the plane of the plasma membrane (referred to as cis interactions) and also with monomers on the surface of apposing cells (referred to as trans interactions) (figure 1). These cis and trans interactions are centred around the cell adhesion recognition (CAR) sequence Histidine–Alanine–Valine (His79–Ala80–Val81) which is found towards the end of the first extracellular (EC1) subdomain of N-cadherin [1,2,13,14]. This sequence was predicted to be directly involved in mediating cell adhesion over two decades ago [14,15]. Recent studies suggest that the His79 and Val81 residues promote cis interactions, whereas the Ala80 residue facilitates trans interactions [2,12,13]. The Ala80 residue is a constituent of a hydrophobic pocket into which docks a tryptophan (Trp2) residue at the N-terminus of an apposed N-cadherin EC1 domain, thus promoting intercellular adhesion (figure 1).

3. Role of N-cadherin in the vasculature

N-cadherin is intimately involved in the formation of blood vessels (a process known as angiogenesis) and the maintenance of their integrity [3,16–18]. Blood microvessels are composed of endothelial and mural cells (pericytes). One of the fundamental functions of pericytes is to stabilize mature microvessels [17,18]. N-cadherin is found at adhesive complexes between endothelial cells and the pericytes that ensheath them [3,16–18]. Inhibition of N-cadherin function destabilizes microvessels [16,18]. For example, antibodies directed against N-cadherin disrupt endothelial cell–pericyte adhesive complexes and cause microvessels to hemorrhage [16]. These observations underline the importance of N-cadherin-mediated endothelial cell–pericyte adhesive interactions to microvessel stability.

4. Role of N-cadherin in tumour growth and progression

Increased tumour growth is dependent on an adequate blood supply [19,20]. Angiogenesis therefore plays a central role in enabling tumour growth. As discussed in §3, N-cadherin is involved in angiogenesis and the maintenance of blood vessel stability. Tumour growth is consequently dependent on N-cadherin. Antagonists of this CAM could conceivably affect tumour growth.

N-cadherin is also expressed by many tumour types: poorly differentiated carcinomas [21], melanoma [22], neuroblastoma [23] and multiple myeloma [6].
Normal epithelial cells express epithelial (E)-cadherin, a CAM closely related to N-cadherin [3,21,24]. Poorly differentiated carcinoma cells cease to express E-cadherin and instead display N-cadherin. Numerous studies have shown that loss of E-cadherin and the aberrant expression of N-cadherin causes tumour cells to lose their polarity, resist apoptosis, become invasive and metastatic. N-cadherin antagonists therefore have the potential of causing tumour cell apoptosis and suppressing metastasis. The ability of N-cadherin to regulate the behaviour of tumour cells has been attributed in part to the interaction with, and activation of, fibroblast growth factor receptor [24–26]. In vitro, further complexities are apparent in the molecular mechanisms underlying the ability of N-cadherin to influence cancer cell metastasis which remain to be fully elucidated. In particular, the N-cadherin-mediated interactions between tumour cells and either endothelial or stromal cells during the metastatic process have not been thoroughly investigated. Studies are also needed to determine the role of N-cadherin in the establishment of metastases at secondary sites [27].

5. N-cadherin antagonists

Several types of N-cadherin antagonists have been discovered. Three types of antagonists are based on the CAR sequence His–Ala–Val (HAV): synthetic linear peptides, synthetic cyclic peptides and non-peptidyl peptidomimetics [28].

Synthetic linear peptides containing the HAV motif were the first peptides shown to be capable of inhibiting N-cadherin-dependent processes [14,29–31]. For example, the decapeptide N-Ac-LRAHADVING-NH2, whose sequence is identical to that found in the EC1 subdomain of human N-cadherin, was shown to block neurite outgrowth [29], myoblast fusion [30] and Schwann cell migration on astrocytes [31].

Synthetic cyclic peptides harbouring the HAV motif were subsequently shown to act as N-cadherin antagonists [32]. The most studied cyclic peptide is N-Ac-CHAVC-NH2 (designated ADH-1) [3]. This cyclic peptide, like the linear peptide, is capable of disrupting a wide variety of N-cadherin-mediated processes. Importantly, ADH-1 has been shown to inhibit angiogenesis [33]. In addition, studies have demonstrated that ADH-1 can cause apoptosis of multiple myeloma [34], neuroblastoma [23] and pancreatic [35] cancer cells. Not all tumour cells displaying N-cadherin undergo apoptosis when exposed to ADH-1. For example, this cyclic peptide does not cause apoptosis in various melanoma cell lines that express N-cadherin [36]. Instead, ADH-1 appears to sensitize these cells to the cytotoxic agent melphalan. The mechanism by which ADH-1 increases the cytotoxic effects of melphalan remains to be elucidated. ADH-1 has been shown to inhibit pancreatic and melanoma tumour growth in animal models when used alone [35], or in combination with cytotoxic agents [36], respectively.

Non-peptidyl peptidomimetics of ADH-1 have also been identified [3,37]. Unlike peptides which are rapidly degraded by gastrointestinal enzymes, such small molecule inhibitors might be suitable for oral administration. The biological properties of these peptidomimetics remain to be determined.

A different type of N-cadherin antagonist has recently been discovered [38]. This type of antagonist is a synthetic linear peptide that harbours a Trp residue in the second position from the N-terminus (similar to N-cadherin). The peptide H-SWTLYTPSQSK-NH2 inhibits endothelial cell tube formation in vitro indicating that it has anti-angiogenic properties [38]. The biological properties of this peptide have not been extensively investigated.

The final type of N-cadherin antagonist to be developed is monoclonal antibodies. Two such monoclonal antibodies directed against the N-cadherin extracellular domain are capable of inhibiting the invasiveness and proliferation of N-cadherin expressing PC3 human prostate carcinoma cells in vitro [39]. These antibodies also suppress PC3 tumour growth and lymph node metastases in vivo.

Collectively, these observations indicate the potential of N-cadherin antagonists for serving as inhibitors of tumour growth and metastasis.

6. N-cadherin antagonists as anti-cancer drugs

The use of N-cadherin antagonists in the clinic as oncology therapeutics is at an early stage of investigation. Only a few clinical trials have been conducted with ADH-1 and there have been no trials with other N-cadherin antagonists. ADH-1 was not toxic at the doses tested in animals [36] and humans [40] indicating that this N-cadherin antagonist does not affect the normal vasculature. There have been indications that ADH-1 might be useful in treating ovarian cancer [40]. In addition, clinical trials testing ADH-1 in combination with melphalan have shown promise in the treatment of melanoma [41].

7. Summary and future directions

The CAM N-cadherin is capable of regulating the proliferation, survival, invasiveness and metastasis of certain tumour cell types, as well as blood vessel formation and stability. Consequently, N-cadherin antagonists can potentially affect many aspects of tumour growth and progression.

The N-cadherin antagonist ADH-1 has been shown to be an anti-angiogenic agent and can cause tumour cell apoptosis. Limited clinical trials with ADH-1 have suggested that it may be useful as an anti-cancer drug. Clearly, more studies are needed to test this hypothesis. It also remains to be determined which tumour types are most responsive to ADH-1.

The identification of orally available, small molecule N-cadherin antagonists is encouraging. Studies are needed to determine the effects of these antagonists on tumours and their vasculature.

References


